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Abstract
Background: Breast cancer survivors often encounter physiological and psychological problems related to their diagnosis and
treatment that can influence long-term prognosis. The aim of this research is to investigate the effects of a lifestyle intervention
on body weight and psychological well-being in women recovering from breast cancer treatment, and to determine the
relationship between changes in these variables and biomarkers associated with disease recurrence and survival.
Methods/design: Following ethical approval, a total of 100 patients will be randomly assigned to a lifestyle intervention
(incorporating dietary energy restriction in conjunction with aerobic exercise training) or normal care control group. Patients
randomised to the dietary and exercise intervention will be given individualised healthy eating dietary advice and written
information and attend moderate intensity aerobic exercise sessions on three to five days per week for a period of 24 weeks.
The aim of this strategy is to induce a steady weight loss of up to 0.5 Kg each week. In addition, the overall quality of the diet
will be examined with a view to (i) reducing the dietary intake of fat to ~25% of the total calories, (ii) eating at least 5 portions
of fruit and vegetables a day, (iii) increasing the intake of fibre and reducing refined carbohydrates, and (iv) taking moderate
amounts of alcohol. Outcome measures will include body weight and body composition, psychological health status (stress and
depression), cardiorespiratory fitness and quality of life. In addition, biomarkers associated with disease recurrence, including
stress hormones, estrogen status, inflammatory markers and indices of innate and adaptive immune function will be monitored.
Discussion: This research will provide valuable information on the effectiveness of a practical, easily implemented lifestyle
intervention for evoking positive effects on body weight and psychological well-being, two important factors that can influence
long-term prognosis in breast cancer survivors. However, the added value of the study is that it will also evaluate the effects of
the lifestyle intervention on a range of biomarkers associated with disease recurrence and survival. Considered together, the
results should improve our understanding of the potential role that lifestyle-modifiable factors could play in saving or prolonging
lives.
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Although the number of women who survive breast can-
cer is increasing, survivors often encounter physiological
and psychological problems related to their diagnosis and
treatment that can influence long-term prognosis. A gain
in body weight [1-6] and psychosocial distress [7-12] are
two commonly encountered adverse responses to breast
cancer diagnosis and treatment that can have a negative
impact on quality of life and survival. Lifestyle strategies
that can attenuate the negative effects of such physical and
mental health outcomes after breast cancer diagnosis
could further improve the quality of life and long-term
prognosis of breast cancer survivors.
Up to 60% of women diagnosed with breast cancer expe-
rience an increase in body weight associated with chemo-
therapy and treatment-related menopause [6] and there is
evidence that heavier women and women who gain
weight after diagnosis have an increased risk of disease
recurrence and death compared to normal weight women
[1-5]. Women with a high body mass index (BMI) have
double the risk of 5-year recurrence and a 60% increased
risk of death over 10 years in comparison to normal-
weight women [5]. Poorer survival in heavier patients
could be due to higher levels of tumor-promoting hor-
mones, consequent to an increased adiposity [13]. There
is evidence that elevated estrogen levels influence the risk
of breast cancer in postmenopausal women [14-16] and it
was recently shown that overweight postmenopausal
breast cancer patients have higher estrogen and testoster-
one levels than normal-weight patients [13]. This led to
the suggestion that circulating estrogen levels could be a
useful biomarker for weight loss intervention studies [13].
Following breast cancer diagnosis or treatment, four in ten
women also experience high levels of emotional distress,
including depression and anxiety [7], which persists for
prolonged periods of time, irrespective of the treatment
outcome [8-12]. Studies have shown that psychosocial
stressors such as depression, anxiety and emotional dis-
tress are associated with impaired immune function [17],
and this could have a direct impact on cancer outcomes
[18,19] and influence the risk of disease re-occurrence and
death [20]. The adverse effect of psychosocial stressors on
immune function is considered to be mediated by excess
secretion of the stress hormone cortisol and the catecho-
lamines [21,22]. Elevated cortisol and catecholamine lev-
els evoked by psychological stressors can significantly
influence immune function, including lymphocyte prolif-
eration and natural killer (NK) cell activity [23-26]. Self-
reported negative mood states have been associated with
lower NK cell activity [27,28] and symptoms of depres-
sion have been linked with increased salivary cortisol [29]
impaired lymphocyte proliferation [30,31] and reduced
NK cell cytotoxicity against tumor cells [32-34]. In addi-
tion, studies have reported abnormal circadian rhythmic-
ity of cortisol in breast cancer patients [35-39] and
flattened or abnormal diurnal salivary cortisol rhythms
have recently been associated with earlier mortality in
breast cancer patients [38] and persistent fatigue in survi-
vors 1–5 years after initial diagnosis [40].
Dietary energy restriction can reduce body weight and
induce a positive effect on psychological well being in
obese women and breast cancer survivors [41-44]. Weight
loss interventions that reduce dietary intake of fat to 18–
25% of the total calories can also evoke a significant
reduction in serum estrogen levels in pre and postmeno-
pausal women [45]. The positive effects of dietary energy
restriction on these physical and emotional sequelae
might be augmented by the implementation of adjunctive
exercise therapy [46,47]. Regular physical activity can help
to control body weight and is known to reduce the risk of
breast cancer [48-53]. Recent evidence also suggests that it
can halve the risk of death in breast cancer patients [54].
The precise mechanisms underpinning the positive effects
of physical activity on breast cancer risk and survival are
unknown, although physical activity has been associated
with a lower concentration of circulating estrogen in some
studies [55,56], as well as lower circulating levels of the
inflammatory mediators, C-reactive protein (CRP) [57-
59] and interleukin-6 (IL-6) [60,61]. Increased CRP levels
are observed in overweight individuals [62,63] and have
been linked with increased cancer risk [64,65] and ele-
vated levels of cortisol in individuals subjected to psycho-
logical stress [66]. Depression enhances the production of
IL-6 [67-69] and this proinflammatory cytokine is also
secreted from adipocytes in proportion to body fat mass
[60]. IL-6 induces CRP synthesis in the liver and can indi-
rectly raise cortisol levels via stimulation of corticotropin-
releasing hormone production [67]. Elevated estrogen
levels may also increase CRP levels through a non-inflam-
matory mechanism [70].
Regular physical activity can also have a positive effect on
psychological health status [71,72] and quality of life [73]
in breast cancer survivors that could enhance immune
function through normalisation of stress hormone levels.
Although there is evidence for decreased cortisol levels
[74,75] and changes in immune cell numbers and func-
tion after psychosocial interventions in breast cancer
patients [76,77], only three studies have investigated the
effects of exercise therapy on immune function in breast
cancer survivors. Peters et al. [78,79] reported an increase
in the percentage of NK cells and an improvement in NK
cell function and monocyte phagocytic capacity that was
accompanied by an increase in 'satisfaction of life' score
after seven months of moderate exercise training, whereas
Nieman et al. [80] did not observe any change in NK cell
function following a shorter period of training. The latterPage 2 of 9
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therapy) group, and neither study measured stress hor-
mone levels in patients. In a more recent study, Fairey et
al. [81] showed that a 15 week programme of aerobic exer-
cise training improved NK cell cytotoxic activity and
peripheral blood lymphocyte function in postmenopau-
sal breast cancer survivors. In sedentary, healthy individu-
als, regular moderate aerobic exercise has been shown to
boost NK cell function [82] and decrease the incidence of
upper respiratory tract infections in previously sedentary
individuals [82-84]. In elderly females however, evidence
for an improvement in immune cell function with aerobic
exercise training is inconclusive, although highly trained
elderly females exhibit superior resting NK cell function
and T cell proliferation responses compared to age-
matched sedentary controls [83]. The lack of intervention
studies incorporating biomarkers of immune function in
women recovering from breast cancer treatment is surpris-
ing, as restoration of lymphocyte and NK cell function
after treatment is predictive of survival [28,85,86] and is
independent of stage of disease and adjunctive treatment
approach [86]. This suggests that lifestyle interventions
which could have an impact on immune function are
worth exploring, as they could have a significant influence
on disease-free survival in breast cancer patients.
Previous studies have investigated the feasibility and effi-
cacy of lifestyle interventions in breast cancer patients and
obese women, in terms of recruitment, compliance and
weight loss [42,43,87,88]. Some studies have also exam-
ined the effects of lifestyle interventions on aspects of psy-
chological [41,47,71,72] and physiological [42,87,88]
well-being. However, no previous studies have investi-
gated the effects of a dietary and exercise intervention on
a range of important prognostic breast cancer biomarkers
that could be strongly influenced by weight loss and
improved psychological well-being. Thus, the aim of the
intended research is to examine the effects of a dietary and
exercise intervention on body weight, indices of psycho-
logical well-being and biomarkers associated with disease
recurrence and physiological health status in female
breast cancer survivors. We hypothesize that the lifestyle
intervention will evoke a reduction in body weight and an
improvement in psychological well-being. Secondly, that
improvements in blood markers of cancer risk and physi-
ological health status (estrogen, CRP, IL-6), psychosocial
stress (cortisol and catecholamines) and immune func-
tion (lymphocyte proliferation and NK cell function) will
be associated with changes in body weight and psycholog-
ical well-being induced by the lifestyle intervention. Con-
sidered together, the results of this study would provide
valuable new information to improve our understanding
of the role that lifestyle-modifiable factors can play in sav-
ing or prolonging the lives of women who have been
treated for breast cancer.
Research design and methods
Overall aim of the study
To examine the effects of a practical lifestyle intervention
that could be easily implemented by overweight or obese
women (BMI > 25) who have undergone breast cancer
treatment, on body weight, indices of psychological well-
being, biomarkers associated with disease recurrence and
physiological health status and quality of life.
Primary aims
1. To examine the effects of a dietary and exercise interven-
tion on body weight and body composition in overweight
or obese women who have undergone breast cancer treat-
ment.
2. To examine the effects of a dietary and exercise interven-
tion on indices of psychological health status and biomar-
kers associated with disease recurrence in overweight or
obese women who have undergone breast cancer treat-
ment.
Secondary aims
1. To examine the relationship between change in body
weight and biomarkers associated with disease recurrence
and physiological health status, including circulating lev-
els of estrogen, CRP and IL-6.
2. To examine the relationship between changes psycho-
logical health status, circulating stress hormones and indi-
ces of immune function.
3. To examine the effects of the dietary and exercise inter-
vention on broader quality of life dimensions.
Patient recruitment
A total of 100 women (BMI > 25) who have undergone
appropriate treatment for operable breast cancer within
the past 3–18 months and are no longer undergoing
chemotherapy or radiation therapy, will be recruited from
the Cancer Research Centre, Weston Park Hospital, Shef-
field University Hospitals NHS Trust. The incidence of
breast cancer within the North Trent Regional Health
Authority area is relatively high, with 850 cases per year
and, on the basis of current rates of breast cancer survival
in South Yorkshire and recruitment rate in our ongoing
trial, we expect to recruit patients at the rate of approxi-
mately six per month for 16 months. Ethical approval has
been obtained from the South Sheffield Research Ethics
Committee and informed consent will be obtained from
all participants before they enter the study.
Randomisation
The minimisation technique [89] will be used to allocate
the patients into one of two groups (i) lifestyle interven-
tion group, incorporating moderate dietary energy restric-Page 3 of 9
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exercise training on 3–5 days per week, or (ii) normal care
control group. Minimisation will be used to balance the
potentially confounding variables of chemotherapy and
treatment with Tamoxifen, aromatase inhibitors or no
hormone therapy across the groups. Randomisation will
be performed by an independent researcher at the Clinical
Trials Research Unit, University of Leeds. The intervention
will last for 24 weeks, with outcome measures being
assessed in the week before and the week after the inter-
vention period and at the mid-intervention time point of
12 weeks. Patients would be recruited over 16 months,
ensuring completion of the trial by 22 months and report-
ing of the data by 24 months.
Details of power calculations and sample size
Body weight was chosen as the primary outcome variable
for calculation of sample size. Utter et al. [88] reported a
8.1 kg reduction in body weight in obese women follow-
ing a 12 week lifestyle intervention, incorporating moder-
ate dietary energy restriction in conjunction with exercise.
Body weight changed from a baseline ± SD level of 89.9 ±
11.7 to 81.8 ± 10.8 kg following the intervention. This
amount of weight loss is associated with improved physi-
cal and psychological health in obese women [41,90]. On
the basis of these data, and taking into account an
expected patient drop-out of up to 10% (based on the
drop-out rate in our ongoing trial with breast cancer sur-
vivors [91]), recruitment of 50 patients for each group will
give us 90% power to detect a difference in body weight of
8 kg at the α level of 0.05.
Patient inclusion criteria
a. Postmenopausal women (confirmed by plasma estra-
diol and gonadotrophin measures in all women aged
<55) with a BMI > 25 and classified as disease stage I-III.
In our experience [91], a high proportion of breast cancer
patients (>80%) meet the BMI criteria and would be suit-
able for participation in the study.
b. Patients must have completed some form of breast can-
cer treatment at least three months, and not more than 18
months ago.
c. Patients on Tamoxifen and other endocrine treatments
but not hormone replacement therapy (HRT) will be
included.
d. Patients must be willing and able to attend supervised
exercise sessions at least 3 times per week for a period of
24 weeks, with the intention of achieving an 80% mini-
mum compliance target for attendance.
e. Patients must be an exercise pre-contemplator, contem-
plator or preparer as defined by the Transtheoretical
Model [92].
Patient exclusion criteria
a. Metastatic breast cancer patients and patients with
inoperable or active loco-regional disease.
b. Patients following alternative/complementary diets or
taking high dose antioxidant supplements.
c. Patients with a physical/psychiatric impairment that
would seriously impair their physical mobility.
d. Patients who are currently suffering from severe nausea,
anorexia or other diseases affecting health (e.g. arthritis
and multiple sclerosis).
e. HRT is not commonly prescribed in women who are
recovering from breast cancer treatment, but use of HRT
or oral contraceptives within the past four months is an
exclusion criteria.
f. Patients who are currently engaged in exercise (two or
more times per week for at least 30 min per session during
the previous 3 months).
Supervised exercise
Patients randomised to the dietary and exercise interven-
tion will attend moderate intensity aerobic exercise ses-
sions on three to five days per week for a period of 24
weeks under the supervision of an exercise scientist. To
account for differences in daily patterns of fatigue and to
minimise attrition, patients will be offered different times
to chose from including week-ends. Patients will be
encouraged to attend five supervised sessions each week,
and must try to attend at least three of the sessions.
Patients not able to attend five supervised sessions will be
counselled on how they can fit an extra 1–2 home/com-
munity-based exercise sessions into their weekly routine.
All sessions of physical activity will be recorded in a phys-
ical activity log and portable pedometers (Omron Health-
care, UK) will be used to determine the number of steps/
distance walked each day. Supervised exercise will be per-
formed in groups of up to eight participants in an exercise
room that contains a variety of aerobic exercise equip-
ment. Each session will comprise a 10 minute warm-up
period (involving light aerobic exercise and gentle range
of motion exercises), 30 min of aerobic exercise at an
intensity of 70%–85% heart rate reserve, and a 10 min
cool-down period involving lower intensity aerobic exer-
cise and some light stretching. Patients will wear heart rate
monitors throughout the exercise sessions and heart rate
and ratings of perceived exertion [93] will be assessed at
regular intervals. In accordance with the recommenda-Page 4 of 9
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of aerobic exercise modalities at these sessions (e.g. step-
ping, cycling, & walking/jogging) to promote enjoyment
and to aid compliance to the programme. Patients will be
encouraged to use their preferred exercise mode to
strengthen the possibility of them maintaining a physi-
cally active lifestyle when the supervised exercise pro-
gramme has been completed. The exercise therapy
sessions will use a variety of cognitive-behavioural tech-
niques for promoting exercise adherence as well as posi-
tive attitudes and experiences.
Dietary energy restriction
Patients randomised to the dietary and exercise interven-
tion will be given individualised healthy eating dietary
advice and written information: 'Weight Loss On A Plate'
(Scottish Dietetic Association). The focus of the verbal
advice will be on reducing the patient's total daily calorie
intake to 600 kcal below their calculated energy require-
ments. Individual energy requirements will be estimated
from formulae of basal metabolic rate and physical activ-
ity level (Scottish Dietetic Association). The aim of this
strategy is to induce a steady weight loss of up to 0.5 Kg
each week. In addition, the overall quality of the diet will
be examined with a view to (i) reducing the dietary intake
of fat to ~25% of the total calories, (ii) eating at least 5
portions of fruit and vegetables a day, (iii) increasing the
intake of fibre and reducing refined carbohydrates, and
(iv) taking moderate amounts of alcohol. Patients will be
required to complete a 3 day diet diary pre intervention
and then weekly throughout the study. The diary will
include one day from the weekend. The diaries from pre
intervention and from weeks 6, 12, 18 and 24 will be ana-
lysed, looking specifically at macronutrients, using Diet-
master software (SDA Solutions, London, UK) computer
dietary analysis package. Once a week, patients will meet
with the research assistant who will discuss their individ-
ual diet diaries with them and identify ways which they
can further improve their nutritional intake. Patients in
the control group will be provided with a general healthy
eating booklet 'Getting the Balance Right' (British Nutri-
tion Foundation).
Outcome measures
The intervention will last for 24 weeks, with all outcome
variables being assessed in the week before and the week
after the intervention period unless otherwise stated.
Primary outcome measure
Body weight and body composition
Patients will be weighed to the nearest 0.05 kg and per-
centage body fat estimated using bio-electrical impedance
(Bodystat 1500, Bodystat Ltd., UK). Waist and hip girths
will be measured to the nearest 0.5 cm using an inelastic
circumference tape. Body weight will be measured at
weekly intervals in the intervention group, whereas bio-
electrical impedance analysis and girth measurements will
only be performed in the week before and after the inter-
vention period and at the mid-intervention time point of
12 weeks.
Other outcome measures
Psychological indices, cardiorespiratory fitness and quality of life
Psychological stress
Psychological stress will be assessed using the Perceived
Stress Scale (PSS) [95]. The PSS is one of the most widely
used psychological instrument for measuring the percep-
tion of stress. It measures the degree to which situations in
an individual's life are appraised as stressful. The items
evaluate how unpredictable, uncontrollable, and over-
loaded respondents find their lives. The scale also
includes a number of direct queries about current levels of
experienced stress. Psychological stress will be assessed in
the week before and after the intervention period and at
the mid-intervention time point of 12 weeks.
Depression
Depression will be assessed using the Beck Depression
Inventory II (BDI-II) [96]. The BDI is a 21-item test which
measures the presence and degree of depression in
respondents. It assesses specific symptoms or attitudes
which appear to be specific to depressed patients, and
which are consistent with descriptions of the depression
contained in the psychiatric literature. Depression will be
assessed in the week before and after the intervention
period and at the mid-intervention time point of 12
weeks.
Cardiorespiratory fitness
Cardiorespiratory fitness will be assessed using a single-
stage submaximal treadmill walking test [97]. Improved
cardiorespiratory fitness in breast cancer patients follow-
ing a 16 week exercise intervention has previously been
demonstrated using this treadmill test [98]. This test is
also being used successfully in our laboratory to assess
physiological adaptations resulting from exercise therapy
in an ongoing breast cancer trial [91].
Quality of life
The Functional Assessment of Cancer Therapy-General
(FACT-G) and (FACT-B) [99] will be used to assess quality
of life. Quality of life is an important clinical outcome and
the FACT-G and FACT-B collectively measure five aspects
of quality of life: physical, functional, emotional, social
and additional concerns specific to breast cancer. Quality
of life will be assessed in the week before and after the
intervention period and at the mid-intervention time
point of 12 weeks.Page 5 of 9
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Physical activity behaviour at the baseline, and at weeks
6,12,18 and 24 will be assessed using the Stanford Seven-
Day Physical Activity Recall (PAR) [100], which has been
used successfully in a number of studies. This will be
administered by telephone in the control patients.
Biomarkers associated with disease recurrence and physiological 
health status
Blood sampling
Blood samples will be drawn from an antecubital vein
between 8:30–10 a.m. in the morning, following a 12
hour overnight fast. Blood will be collected into Vacu-
tainer tubes (BD Biosciences Ltd, Oxford, U.K.), contain-
ing EDTA for leukocyte counts, plasma biomarker and
immune function analysis. NK cells and T lymphocytes
will be isolated from whole blood within 2 h of venepunc-
ture for analysis of NK Cell and T cell function. Plasma
samples will be stored at -80°C for batch-analysis at a
later date. All flow cytometric analyses, leukocyte func-
tional assays and enzyme immunoassays will be per-
formed in the Biomedical Sciences Research Centre,
Sheffield Hallam University, under the supervision of one
of the key personnel, Professor Nicola Woodroofe.
Estrogen, stress hormones and inflammatory markers
Plasma IL-6, epinephrine and norepinephrine levels will
be measured using commercially available enzyme-linked
immunoassays (ELISA) kits (Bio-Quant Inc and Immuno-
biological Laboratories, Hamburg, R & D Systems UK)
and plasma hs-CRP will be measured by the Immunology
Department, Northern General Hospital, Sheffield using a
turbidimetric assay. Serum estradiol, estrone and estrone
sulphate will be measured using high-sensitivity ELISA
kits Bio-Quant Inc., CA, USA and Diagnostic Systems Lab-
oratories Inc., OBI-DSL, Oxon, UK). Salivary cortisol lev-
els will be measured on each of three consecutive days at
0800, 1200, 1700 and 2100 hours and the slope of diur-
nal cortisol variation will be determined from the pooled
saliva samples at each daily time point using a regression
of the log-transformed cortisol concentrations on sample
collection time [38]. Easy-Reach Radio Pagers (British Tel-
ecommunications Plc, UK) will be used to signal saliva
collection times and the importance of collecting samples
at the designated times and recording the actual sample
collection time will be emphasized. Saliva samples will be
refrigerated, before collection within 2–4 days and frozen
at -70°C until analysis[40] using a high sensitivity salivary
cortisol enzyme immunoassay (Salimetrics LLC, PA,
USA).
Differential leukocyte counts
Differential leukocyte counts and other haematological
parameters will be measured within 6 hours of blood
sampling in the Department of Haematology, Royal Hal-
lamshire Hospital (CPA accredited) using a Coulter STKS
automated haematological analyser (Beckman Coulter
U.K. Ltd, High Wycomb, U.K.) which is calibrated on a
daily basis.
Lymphocyte phenotyping
The proportion of NK (CD3-CD16+CD56+) and T cell sub-
sets (CD3+CD4+; CD3+CD8+) will be measured using
whole blood multicolour flow cytometry. Whole blood
will be collected into EDTA anticoagulant and 100 µl aliq-
uots incubated with appropriate combinations of fluoro-
chrome (PE/FITC/PerCP)-conjugated monoclonal
antibodies (mAb) to CD3, CD4, CD8, CD16 and CD56
using triple antibody sets (BD Biosciences Ltd). Lym-
phocyte and monocyte populations will be located on the
basis of forward and side scatter and dead cells will be
excluded. The proportion of cells expressing the given
combination of antigens will be determined using a BD
Biosciences FACSort™ flow cytometer and CELLQuest
Pro™ data acquisition and analysis software. Appropriate
isotype matched, negative control antibodies will be
included in all analyses.
NK cell activity
NK cell activity will be determined as the capacity of
peripheral blood mononuclear cells to kill human eryth-
roleukemia K562 target cells using flow cytometry, essen-
tially as described previously [101]. Briefly, K562 cells in
the log phase of growth will be harvested, washed and
stained with the stable membrane dye PKH2 (BD Bio-
sciences). Human peripheral blood mononuclear cells
will be isolated by density gradient centrifugation on
Ficoll (Sigma UK) and monocytes/macrophages will be
removed by plastic adherence (37°C, 1 h). Two-fold serial
dilutions of effector cells (800 µl; starting at 106 cells/ml)
will be placed in 12 × 75 mm polystyrene tubes with 100
µl PKH2 labelled target cells (105 cells) to give a range of
effector to target cell ratios (80:1 to 5:1). Samples will be
incubated at 37°C for 4 h after which time the DNA stain
propidium iodide (which only stains non-viable cells)
will be added. The proportion of PKH2+PI+ (non-viable)
K562 cells at each effector to target cell ratio will be deter-
mined after 15 min by flow cytometry. Appropriate con-
trols (effector cells only; target cells only) will be included
in all experiments.
Lymphocyte proliferation assays
Peripheral blood lymphocyte proliferative responses to
recall antigen (purified protein derivative, PPD) will be
determined. Peripheral blood mononuclear cells will be
isolated as described above and 105 cells incubated for 7
days (37°C, 5% CO2) with an appropriate concentration
of PPD (~1 µg/ml) in 96-well microtitre plates. Antigen
non-specific proliferation will be determined by incubat-
ing cells with plate-bound anti-CD3 mAb and solublePage 6 of 9
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both assays, proliferation will be determined by preincu-
bating cells with 5,6-carboxyfluorescein diacetate succim-
idyl ester (CFSE)(Molecular Probes) and subsequent
measurement of the amount of dye per cell by flow
cytometry [102].
Data Analysis
A mixed factorial ANOVA will be used to assess (i)
changes from baseline on all outcome measures following
the intervention within patient groups, and (ii) differ-
ences in outcome measures between patients in the life-
style intervention and control groups post intervention.
Pearson product moment correlation coefficients (r) will
be calculated to determine bivariate relationships among
changes in the variables. Statistical significance will be set
at p < 0.05. All data will be analysed using the SPSS statis-
tical package (SPSS UK Ltd, Woking, U.K.).
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